Trial · NCT01865747
Adverse events472
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 472
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Hypothyroidism | Endocrine disorders | Cabozantinib (XL184) | 68 | 331 | 68 |
| other | Hypothyroidism | Endocrine disorders | Everolimus (Afinitor) | 2 | 322 | 2 |
| other | Abdominal Pain | Gastrointestinal disorders | Cabozantinib (XL184) | 50 | 331 | 50 |
| other | Abdominal Pain | Gastrointestinal disorders | Everolimus (Afinitor) | 30 | 322 | 30 |
| other | Abdominal Pain Upper | Gastrointestinal disorders | Cabozantinib (XL184) | 26 | 331 | 26 |
| other | Abdominal Pain Upper | Gastrointestinal disorders | Everolimus (Afinitor) | 7 | 322 | 7 |
| other | Constipation | Gastrointestinal disorders | Cabozantinib (XL184) | 83 | 331 | 83 |
| other | Constipation | Gastrointestinal disorders | Everolimus (Afinitor) | 61 | 322 | 61 |
| other | Diarrhoea | Gastrointestinal disorders | Cabozantinib (XL184) | 245 | 331 | 245 |
| other | Diarrhoea | Gastrointestinal disorders | Everolimus (Afinitor) | 88 | 322 | 88 |
| other | Dyspepsia | Gastrointestinal disorders | Cabozantinib (XL184) | 40 | 331 | 40 |
| other | Dyspepsia | Gastrointestinal disorders | Everolimus (Afinitor) | 15 | 322 | 15 |
| other | Flatulence | Gastrointestinal disorders | Cabozantinib (XL184) | 32 | 331 | 32 |
| other | Flatulence | Gastrointestinal disorders | Everolimus (Afinitor) | 6 | 322 | 6 |
| other | Nausea | Gastrointestinal disorders | Cabozantinib (XL184) | 164 | 331 | 164 |
| other | Nausea | Gastrointestinal disorders | Everolimus (Afinitor) | 89 | 322 | 89 |
| other | Vomiting | Gastrointestinal disorders | Cabozantinib (XL184) | 105 | 331 | 105 |
| other | Vomiting | Gastrointestinal disorders | Everolimus (Afinitor) | 44 | 322 | 44 |
| other | Fatigue | General disorders | Cabozantinib (XL184) | 185 | 331 | 185 |
| other | Fatigue | General disorders | Everolimus (Afinitor) | 149 | 322 | 149 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01865747/events